We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

66 hedge funds and large institutions have $314M invested in Monte Rosa Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,345% more call options, than puts

Call options by funds: $489K | Put options by funds: $11K

53% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.99% less ownership

Funds ownership: 86.18% → 85.19% (-0.99%)

4% less capital invested

Capital invested by funds: $328M → $314M (-$14.1M)

6% less funds holding

Funds holding: 70 → 66 (-4)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

Holders
66
Holders Change
-4
Holders Change %
-5.71%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
26
Reduced
17
Closed
10
Calls
$489K
Puts
$11K
Net Calls
+$478K
Net Calls Change
+$478K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$8.01M
2
Millennium Management
Millennium Management
New York
+$3.06M
3
BlackRock
BlackRock
New York
+$1.07M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$277K
5
State Street
State Street
Massachusetts
+$273K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$833K
2
O
OrbiMed
New York
-$750K
3
UOC
UBS O'Connor
Illinois
-$748K
4
HF
HRT Financial
New York
-$700K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$666K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$58.5M -$90.9K -10,907 -0.1%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$47.3M +$104K +12,484 +0.2%
ACA
3
Avoro Capital Advisors
New York
$32.9M +$8.01M +961,667 +29%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$28M -$666K -79,956 -2%
BlackRock
5
BlackRock
New York
$27.4M +$1.07M +128,304 +4%
CAM
6
Cormorant Asset Management
Massachusetts
$22M -$833K -100,000 -3%
T. Rowe Price Investment Management
7
T. Rowe Price Investment Management
Maryland
$14.7M +$81.3K +9,761 +0.5%
ACM
8
Aisling Capital Management
New York
$11.2M – – –
AI
9
Alphabet Inc
California
$11.1M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$10.9M +$159K +19,047 +1%
RI
11
RTW Investments
New York
$9.24M – – –
Citadel Advisors
12
Citadel Advisors
Florida
$7.41M +$177K +21,239 +2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$4.29M +$277K +33,235 +6%
State Street
14
State Street
Massachusetts
$3.94M +$273K +32,805 +7%
WP
15
Woodline Partners
California
$3.89M +$74.5K +8,940 +2%
CC
16
Casdin Capital
New York
$3.89M – – –
Millennium Management
17
Millennium Management
New York
$2.99M +$3.06M +367,221 +1,416%
Northern Trust
18
Northern Trust
Illinois
$1.94M +$58K +6,961 +3%
Charles Schwab
19
Charles Schwab
California
$1.71M +$93.9K +11,269 +5%
TD Asset Management
20
TD Asset Management
Ontario, Canada
$1.07M – – –
N
21
Nuveen
North Carolina
$905K -$115K -13,849 -10%
Morgan Stanley
22
Morgan Stanley
New York
$820K -$120K -14,426 -12%
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$759K -$825 -99 -0.1%
VOYA Investment Management
24
VOYA Investment Management
Georgia
$703K -$57.3K -6,874 -7%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$680K +$13.8K +1,660 +2%
1
2 3 4

GLUE Hedge Fund Activity: Q4 2022 in Review

66 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2022, worth a combined $314M — down 4.3% from $328M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GLUE and 6 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 26 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $8.01M. The largest seller was Cormorant Asset Management, cutting an estimated $833K.

  • 66 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2022, down from 70 in Q3 2022.
  • Funds reported $314M of Monte Rosa Therapeutics stock for Q4 2022, down 4.3% quarter-over-quarter.
  • 6 funds opened new Monte Rosa Therapeutics positions in Q4 2022 and 10 closed out, a net change of -4 holders.
  • The largest Monte Rosa Therapeutics buyer in Q4 2022 was Avoro Capital Advisors, an estimated $8.01M added.
  • The largest Monte Rosa Therapeutics seller in Q4 2022 was Cormorant Asset Management, an estimated $833K sold.

Based on aggregated 13F filings for Q4 2022.